Hepatitis C drug discovery: In vitro and in vivo systems and drugs in the pipeline

Expert Review of Anti-Infective Therapy

Volumn 2, Issue 3, 2004, Pages 375-388

  Huang, Mingjun ^a   Deshpande, Milind ^a  

^a Departments of Antiviral Drug Discovery   (United States)

Author keywords

Antiviral drug discovery; HCV; in vitro system; in vivo system; Specific antiviral inhibitor

Indexed keywords

ALPHA INTERFERON; ANTIVIRUS AGENT; CILUPREVIR; FURAPROFEN; HCV 086; HCV 371; HEPATITIS C ANTIBODY; HEPATITIS C VACCINE; HEPTAZYME; IMMUNOMODULATING AGENT; INOSINATE DEHYDROGENASE INHIBITOR; ISIS 14803; JTK 003; NM 107; OLIGODEOXYNUCLEOTIDE DERIVATIVE; PEGINTERFERON; PLACEBO; PRODRUG; PROTEINASE INHIBITOR; R 1479; RECEPTOR BLOCKING AGENT; RIBAVIRIN; RNA DIRECTED DNA POLYMERASE INHIBITOR; TOLL LIKE RECEPTOR; UNCLASSIFIED DRUG; VALOPICITABINE; VX 950;

CARDIOTOXICITY; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DRUG DESIGN; DRUG EFFICACY; DRUG RESEARCH; DRUG RESPONSE; DRUG SPECIFICITY; DRUG TARGETING; DRUG TOLERABILITY; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; IN VITRO STUDY; IN VIVO STUDY; NAUSEA; NONHUMAN; PREDICTION; REVIEW; TREATMENT OUTCOME; VOMITING;

EID: 2942618320     PISSN: 14787210     EISSN: None     Source Type: Journal    
DOI: 10.1586/14787210.2.3.375     Document Type: Review

References (92)

1. Cohen J. The scientific challenge of hepatitis C. Science 285, 26-30 (1999).
2. Alter MJ. Epidemiology of hepatitis C. Hepatology 26(Suppl. 1), 62-65 (1997).
3. WHO. Hepatitis C: global prevalence. Wkly Epidemiol. Rec. 72, 341-344 (1997).
4. Hoofnagle JH, Mullen KD, Jones DB et al. Treatment of chronic non-A, non-B hepatitis with recombinant human α-interferon. A preliminary report. N. Engl. J. Med. 315(25), 1575-1578 (1986).
5. 2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N. Engl. J. Med. 339(21), 1485-1492 (1998).
6. 2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT). Lancet 352 (9138), 1426-1432 (1998).
7. 2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 358(9286), 958-965 (2001 ).
8. Fried MW, Shiffman ML, Reddy KR et al. Peginterferon-α2a plus ribavirin for chronic hepatitis C virus infection. N. Engl. J. Med. 347(13), 975-982 (2002).
9. 2b and ribavirin. Expert Rev. Anti-infect. Ther. 2(1), 17-25 (2004).
10. Griffin SD, Beales LP, Clarke DS et al. The p7 protein of hepatitis C virus forms an ion channel that is blocked by the antiviral drug, amantadine. FEBS Lett. 535, 34-38 (2003).
11. Sakai A, Claire MS, Faulk K et al. The p7 protein of hepatitis C virus is critical for infectivity and contains functionally important genotype-specific sequences. 10th International Meeting on Hepatitis C Virus and Related Viruses. (2003) (Abstract O40).
12. Egger D, Wolk B, Gosert R et al. Expression of hepatitis C virus proteins induces distinct membrane alterations including a candidate viral replication complex. J. Virol. 76, 5974-5984 (2002).
13. Hugle T, Fehrmann F, Bieck E et al. The hepatitis C virus nonstructural protein 4B is an integral endoplasmic reticulum membrane protein. Virology 284, 70-81 (2001).
14. Einav S, Elazar M, Glann J. A nucleotide binding motif in HCV NS4B mediates HCV RNA replication. 10th International Meeting on Hepatitis C Virus and Relate d Viruses. (2003) (Abstract O41).
15. He Y, Katze MG. To interfere and to anti-interfere: the interplay between hepatitis C virus and interferon. Viral Immunol. 15, 95-119 (2002).
16. Xu Z, Choi J, Yen TS et al. Synthesis of a novel hepatitis C virus protein by ribosomal frameshift. EMBO J. 20(14), 3840-3848 (2001).
17. Varaklioti A, Vassilaki N, Georgopoulou U et al. Alternate translation occurs within the core-coding region of the hepatitis C viral genome. J. Biol. Chem. 277(20), 17713-17721 (2002).
18. Vassilaki N, Mavromara P. Two alternative translation mechanisms are responsible for the expression of the HCV ARFP/F/core+1 coding open reading frame. J. Biol. Chem. 278(42), 40503-40513 (2003).
19. Lu HH, Wimmer E. Poliovirus chimeras replicating under the translational control of genetic elements of hepatitis C virus reveal unusual properties of the internal ribosomal entry site of hepatitis C virus. Proc. Natl Acad. Sci. USA 93, 1412-1417 (1996).
20. Zhao WD, Wimmer E, Lahser FC. Poliovirus/Hepatitis C virus (internal ribosomal entry site-core) chimeric viruses: improved growth properties through modification of a proteolytic cleavage site and requirement for core RNA sequences but not for core-related polypeptides. J. Virol. 73(2), 1546-1554 (1999).
21. Troxell J, Wenzel M, Huang M. A system for evaluation of compounds against HCV internal ribosomal entry site (IRES) activity. Antivir. Res. 46, A64 (1999).
22. Jubin R. Targeting hepatitis C virus translation: stopping HCV where it starts. Curr. Opin. Investig. Drugs 4(2), 162-167 (2003).
23. Thibeault D, Maurice R, Pilote L et al. In vitro characterization of a purified NS2/3 protease variant of hepatitis C virus. J. Biol. Chem. 276(49), 46678-46684 (2001).
24. Pallaoro M, Lahm A, Biasiol G et al. Characterization of the hepatitis C virus NS2/3 processing reaction by using a purified precursor protein. J. Virol. 75(20), 9939-9946 (2001).
25. Wenzel M, Troxell J, Buckheit R, Huang M. Establishment of a cell based assay for evaluation of compounds against HCV NS2-3 protease activity. Antivir. Ther. 4(Suppl.), A95 (1999).
26. Whitney M, Stack JH, Darke PL et al. A collaborative screening program for the discovery of inhibitors of HCV NS2/3 ciscleaving protease activity. J. Biomol. Screen. 7(2), 149-154 (2002).
27. Flint M, Maidens C, Loomis-Price LD et al. Characterization of hepatitis C virus E2 glycoprotein interaction with a putative cellular receptor, CD81. J. Virol. 73, 6235-6244 (1999).
28. Pileri P, Uematsu Y, Compagnoli S et al. Binding of hepatitis C virus to CD81. Science 282, 938-941 (1998).
29. Zhang J, Randall G, Higginbottom A et al. CD81 is required for hepatitis C virus glycoprotein-mediated viral infection. J. Virol. 78(3), 1448-1455 (2004).
30. Scarselli E, Ansuini H, Cerino R et al. The human scavenger receptor class B Type I is a novel candidate receptor for the hepatitis C virus. EMBO J. 21, 5017-5025 (2002).
31. Gardner JP. Durso RJ, Arrigale RR et al. L-SIGN (CD 209L) is a liver-specific capture receptor for hepatitis C virus. Proc. Natl Acad. Sci. USA 100, 4498-4503 (2003).
32. Lozach PY, Lortat-Jacob H, Lacroix De Lavallette et al. DC-SIGN and L-SIGN are high-affinity binding receptors for hepatitis C virus glycoprotein E2. J. Biol. Chem. 278, 20358-20366 (2003).
33. Pohlmann S, Zhang J, Baribaud F et al. Hepatitis C virus glycoproteins interact with DC-SIGN and DC-SIGNR. J. Virol. 77, 4070-4080 (2003).
34. Agnello V, Abel G, Elfahal M et al. Hepatitis C virus and other flaviviridae viruses enter cells via low density lipoprotein receptor. Proc. Natl Acad. Sci. USA 96, 12766-12771 (1999).
35. Wunschmann S, Medh JD, Klinzmann D et al. Characterization of hepatitis C virus (HCV) and HCV E2 interactions with CD81 and the low-density lipoprotein receptor. J. Virol. 74, 10055-10062 (2000).
36. Bartosch B, Dubuisson J, Cosset FL. Infectious hepatitis C virus pseudoparticles containing functional E1-E2 envelope protein complexes. J. Exp. Med. 197, 633-642 (2003).
37. Hsu MJ, Zhang M, Flint C et al. Hepatitis C virus glycoproteins mediate pH-dependent cell entry of pseudotyped retroviral particles. Proc. Natl Acad. Sci. USA 100, 7271-7276 (2003).
38. Lohmann V, Korner F, Koch J et al. Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line. Science 285(5424), 110-113 (1999).
39. Behrens SE, Grassmann CW, Thiel HJ et al. Characterization of an autonomous subgenomic pestivirus RNA replicon. J. Virol. 72(3), 2364-2372 (1998).
40. Blight KJ, Kolykhalov AA, Rice CM. Efficient initiation of HCV RNA replication in cell culture. Science 290, 1972-1974 (2000).
41. Krieger N, Lohmann V, Bartenschlager R. Enhancement of hepatitis C virus RNA replication by cell culture-adaptive mutations. J. Virol. 75, 4614-4624 (2001).
42. Lohmann V, Körner F, Dobierzewska A, Bartenschlager R. Mutations in hepatitis C virus RNAs conferring cell culture adaptation. J. Virol. 75, 1437-1449 (2001).
43. Guo JT, Bichko VV, Seeger C. Effect of α-interferon on the hepatitis C virus replicon. J. Virol. 75, 8516-8523 (2001).
44. Pietschmann T, Lohmann V, Kaul A et al. Persistent and transient replication of full length hepatitis C virus genomes in cell culture. J. Virol. 76(8), 4008-4021 (2002).
45. Lohmann V, Hoffmann S, Herian U et al. Viral and cellular determinants of hepatitis C virus RNA replication in cell culture. J. Virol. 77(5), 3007-3019 (2003).
46. Murray EM, Grobler JA, Markel EJ et al. Persistent replication of hepatitis C virus replicons expressing the β -lactamase reporter in subpopulations of highly permissive Huh7 cells. J. Virol. 77(5), 2928-2935 (2003).
47. Yi M, Bodola F, Lemon SM. Subgenomic hepatitis C virus replicons inducing expression of a secreted enzymatic reporter protein. Virology 304(2), 197-210 (2002).
48. Ikeda M, Yi M, Li K, Lemon SM. Selectable subgenomic and genome-length dicistronic RNAs derived from an infectious molecular clone of the HCV-N strain of hepatitis C virus replicate efficiently in cultured Huh7 cells. J. Virol. 76, 2997-3006 (2002).
49. Kishine H, Sugiyama K, Hijikata M et al. Subgenomic replicon derived from a cell line infected with the hepatitis C virus. Biochem. Biophys. Res. Commun. 293, 993-999 (2002).
50. Kato N, Sugiyama K, Namba K et al. Establishment of a hepatitis C virus subgenomic replicon derived from human hepatocytes infected in vitro. Biochem. Biophys. Res. Commun. 306, 756-766 (2003).
51. Blight KJ, McKeating JA, Marcotrigiano J, Rice CM. Efficient replication of hepatitis C virus genotype 1a RNAs in cell culture. J. Virol. 77, 3181-3190 (2003).
52. Kato T, Date T, Miyamoto M et al. Efficient replication of the genotype 2a hepatitis C virus subgenomic replicon. Gastroenterology 125, 1808-1817 (2003).
53. Flores O, Impact of HCV Genetic heterogenecity on efficacy of next generation of antiviral agents. HEP DART 2003. Kauai, Hawaii, USA. 14th-18th December 2003.
54. Zhu Q, Guo JT, Seeger C. Replication of hepatitis C virus subgenomes in nonhepatic epithelial and mouse hepatoma cells. J. Virol. 77(17), 9204-9210 (2003).
55. Carroll SS, Tomassini JE, Bosserman M et al. Inhibition of hepatitis C virus RNA replication by 2′-modified nucleoside analogs. J. Biol. Chem 278, 11979-11984 (2003).
56. Trozzi C, Bartholomew L, Ceccacci A et al. In vitro selection and characterization of hepatitis C virus serine protease variants resistant to an active-site peptide inhibitor. J. Virol. 77(6), 3669-3679 (2003).
57. Yang W, Liu D, Sun Y et al. Two simple, inexpensive and medium to high throughput methods to quantify the amount of HCV RNA and NPTII in HCV replicon containing cells. 10th International Meeting on Hepatitis C Virus and Relate d Viruses. Kyoto, Japan. (2003) (Abstract P-211).
58. Nguyen TT, Gates AT, Gutshall LL et al. Resistance profile of a hepatitis C virus RNA-dependent RNA polymerase benzothiadiazine inhibitor. Antimicrob. Agents Chemother. 47(11), 3525-3530 (2003).
59. Migliaccio G, Tomassini JE, Carroll SS et al. Characterization of resistance to nonobligate chain-terminating ribonucleoside analogs that inhibit hepatitis C virus replication in vitro. J. Biol. Chem. 278(49), 49164-49170 (2003).
60. Tomei L, Altamura S, Bartholomew L et al. Mechanism of action and antiviral activity of benzimidazole-based allosteric inhibitors of the hepatitis C virus RNA-dependent RNA polymerase. J. Virol. 77(24), 13225-13231 (2003).
61. Tomei L, Altamura S, Bartholomew L et al. Characterization of the inhibition of hepatitis C virus RNA replication by non-nucleosides. J. Virol 78 (2), 938-946 (2004).
62. Lin C, Lin K, Luang YP et al. In vitro resistance studies of hepatitis C virus serine protease inhibitors, VX-950 and BILN 2061: structural analysis indicates different resistance mechanisms. J. Biol. Chem. (Epub ahead of print) (2004).
63. Lamarre D, Anderson PC, Bailey M et al. An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus. Nature 426(6963), 186-189 (2003).
64. Lin K, Perni RB, Kwong AD et al. Synergistic inhibition of HCV replication by a HCV NS3 4A protease inhibitor and interferon-α in replicon cells. 10th International Meeting on Hepatitis C Virus and Related Viruses. Kyoto, Japan. 2nd - 6th December 2003.
65. Carloni G, Iacovacci S, Sargiacomo M et al. Susceptibility of human liver cell cultures to hepatitis C virus infection. Arch. Virol. 8(Suppl.), 31-39 (1993).
66. Iacovacci S, Manzin A, Barca S et al. Molecular characterization and dynamics of hepatitis C virus replication in human fetal hepatocytes infected in vitro. Hepatology 26, 1328-1337 (1997).
67. Fournier C, Sureau C, Coste J et al. In vitro infection of adult normal human hepatocytes in primary culture by hepatitis C virus. J. Gen. Virol. 79(Part 10), 2367-2374 (1998).
68. Rumin S, Berthillon P, Tanaka E et al. Dynamic analysis of hepatitis C virus replication and quasispecies selection in long-term cultures of adult human hepatocytes infected in vitro. J. Gen. Virol. 80(Pt 11), 3007-3018 (1999).
69. Caster VC, Fournier A, Soulier R et al. Alpha interferon inhibits hepatitis C virus replication in primary human hepatocytes infected in vitro. J. Virol. 76, 8189-8199 (2002).
70. Kwong A, Bym R, Alford J et al. Development of a hepatitis C virus infection virus assay for drug discovery. 10th Internal Meeting on HCV and Related Viruses. (2003) (Abstract P167).
71. Sung VM, Shimodaira S, Doughty AL et al. Establishment of B-cell lymphoma cell lines persistently infected with hepatitis C virus in vivo and in vitro: the apoptotic effects of virus infection. J. Virol. 77(3), 2134-2146 (2003).
72. Mercer DF, Schiller DE, Elliott JF et al. Hepatitis C virus replication in mice with chimeric human livers. Nature Med. 7, 727-933 (2001).
73. Kneteman NM, His B, Schiller D et al. Validation of Alb/uPA mouse model for treatment and prevention of viral hepatitis. 10th internal meeting on HCV and Related Viruses. (2003) (Abstract P-187).
74. Beames B, Chavez D, Lanford RE. GB virus B as a model for hepatitis C virus. ILAR J. 42, 152-160 (2001).
75. Bukh J, Apgar CL, Govindarajan S, Purcell RH. Host range studies of GB virus-B hepatitis agent, the closest relative of hepatitis C virus, in New World monkeys and chimpanzees. J. Med. Virol. 6, 694-697 (2001).
76. Lanford RE, Chavez D, Notvall L, Brasky KM. Comparison of tamarins and marmosets as hosts for GBV-B infections and the effect of immune suppression on the duration of viremia. Virology 311, 72-80 (2003).
77. Bright H, Carroll AR, Watts PA, Fenton RJ. Development of a GB virus B marmoset model and its validation with a novel series of hepatitis C virus NS3 protease inhibitors. J. Virol. 78(4), 2062-2071 (2004).
78. Tomassi De, Pizzuti AM, Graziani A et al. Cell clones selected from the Huh7 human hepatoma cell line support efficient replication of a subgenomic GB virus B replicon. J. Virol. 76, 7736-7746 (2002).
79. Tomassi A, Pizzuti M, Traboni C. Hep3B human hepatoma cells support replication of the wild type and a 5′-end deletion mutant GB virus B replicon. J. Virol. 77(22), 11875-11881 (2003).
80. Thibeault D, Bousquet C, Gingras R et al. Sensitivity of NS3 Serine Proteases from Various Hepatitis C Virus Genotypes to the Antiviral Compound BILN 2061. 54th Annual Meeting of the American Association for the Study of Liver Diseases. (2003) (Abstract 300A).
81. Benhamou Yves. Short-term anti-HCV activity and safety of BILN 2061 a novel oral HCV serine protease inhibitor. HEP DART 2003 Frontiers In Drug Development For Viral Hepatitis Conference. Kauai, Hawaii, USA. 14th-18th December 2003.
82. Reiser M, Hinrichsen H, Benhamous Y et al. Antiviral effect of BILN 2061, a novel HCV serine protease inhibitor, after oral treatment over 2 days in patients with chronic hepatitis C, nongenotype 1. 54th Annual Meeting of the American Association for the Study of Liver Diseases. (2003) (Abstract 136A).
83. Wedemeyer H, Hochschule M, Erhardt A et al. Safety and antiviral effect of BILN 2061, a novel HCV serine protease inhibitor, after oral treatment over 2 days in patients with chronic hepatitis C, genotype 1 and liver cirrhosis. 54th Annual Meeting of the American Association for the Study of Liver Diseases. (2003) (Abstract 294A).
84. Perni RB, Chandorkar G, Chaturvedi PR et al. VX-950: the discovery of an inhibitor of the hepatitis C NS3•4a protease and a potential heptitis C virus therapeutic. 54th Annual Meeting of the American Association for the Study of Liver Diseases. (2003) (Abstract 972A).
85. Lin K, Gates CA, Luong YP et al. VX-950: a tight-binding HCV protease inhibitor with a superior sustained inhibitory response in HCV replicon cells. 54th Annual Meeting of the American Association for the Study of Liver Diseases. (2003) (Abstract 137A).
86. Standring DN, Lanford R, Wright T et al. NM283 has potent antiviral activity against chronic hepatitis C virus genotype 1 infection in the chimpanzee. HEP DART 2003 Frontiers In Drug Development For Viral Hepatitis Conference. Kauai, Hawaii, USA. 14th-18th December 2003.
87. Godofsky E, Afdhal N, Rustgi V et al. First clinical results for a novel antiviral treatment for hepatitis C: a Phase I/II dose escalation trial assessing tolerance, pharmacokinetics and antiviral activity of NM283. 39th Annual Meeting of the European Association for the Study of the Liver. Berlin, Germany. 14-18 April 2004.
88. McHutchison JG, Patel K. Future therapy of hepatitis C. Hepatology 36, S245-S252 (2002).
89. McHutchison JG, Pockros PJ, Patel K et al. A Phase 1b dose escalation trial of ISIS 14803, an antisense inhibitor of HCV, in patients with chronic HCV: final report. Hepatology 36, 303A (2002).
90. Gordon SC, Bacon BR, Jacobson IM et al. A Phase II, 12-week study of ISIS 14803, an antisense inhibitor of HCV for the treatment of chronic hepatitis C. Hepatology 36 (2002) (Abstract 362A).
91. Gordon SC, Bacon BR, Jacobson IM et al. Treatment of chronic hepatitis C with ISIS 14803, an antisense inhibitor of HCV, given for 12 weeks. 54th Annual Meeting of the American Association for the Study of Liver Diseases, (2003) (Abstract 312A).
92. Bartenschlager R. Hepatitis C virus replicons: potential role for drug development. Naure Rev. Drug Discov. 1(11), 911-916 (2002).